Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Annual Report 2022

In this guide

In this guide

- 1. About the Committees 2022
- 2. COT Preface 2022
- 3. COT evaluations 2022
- 4. Committee Procedures 2022
- 5. Ongoing Work COT 2022
- 6. Other Committee Activities Joint Expert Groups and Presentations -2022
- 7. 2022 Membership of the Committee on Toxicity of Chemicals in Food,
 Consumer Products and the Environment
- 8. <u>Committee on Mutagenicity of chemicals in Food, Consumer Products and</u> the Environment Annual Report 2022
- 9. Ongoing work COM 2022
- 10. COM Evaluations 2022
- 11. Horizon scanning: meetings and workshops COM 2022
- 12. OECD guidelines COM 2022
- 13. 2022 Membership of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment
- 14. <u>Committee on Carcinogenicity of Chemicals in Food, Consumer Products and</u> the Environment Annual Report 2022
- 15. COC Ongoing Topics 2022
- 16. COC Joint ongoing topics 2022
- 17. COC Workshop 2022
- 18. Joint session COC 2022
- 19. Horizon scanning COC 2022
- 20. Working Groups COC 2022

- 21. Guidance statements COC 2022
- 22. 2022 Membership of the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment

Preface



Head and shoulders image of Professor David Harrison in front of a grey background wearing a white shirt with a blue and yellow striped tie.

The Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC) evaluates chemicals for their potential to cause cancer in humans at the request of UK Government Departments and Agencies.

The membership of the Committee, agendas and minutes of meetings, and statements are all published on the internet: <u>Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment - GOV.UK (www.gov.uk)</u>.

In practice the work of the Committee is divided into three sections: (i) response to enquiries regarding specific chemicals or classes of chemicals; (ii) revision and updating of guideline documents that inform industry, regulators and public on what kinds of evidence help to determine the potential to cause cancer and how to evaluate them; (iii) review of underpinning science and recent technology to see if we can develop more appropriate, safe ways to assess the potential of chemicals to cause cancer, thereby increasing safety, reducing use of animals, increasing speed and reducing costs.

I am grateful to Members, Secretariat and other advisors and contributors, without all of whom the Committee could not operate effectively.

Professor David Harrison

MD DSc FRCPath FRCPEd FRCSEd